Keyphrases
Acute Lymphoblastic Leukemia
100%
L-asparaginase
35%
Thromboembolism
31%
Pediatric Hematology
25%
Pediatric Oncology
25%
Older Adults
25%
Maintenance Therapy
17%
Childhood Acute Lymphoblastic Leukemia
17%
Confidence Interval
14%
6-mercaptopurine (6-MP)
12%
Leukemia Therapy
11%
Asparaginase-associated Pancreatitis
11%
Osteonecrosis
8%
6-Thioguanine (6-TG)
7%
Hazard Ratio
7%
Overall Survival
7%
Hepatotoxicity
7%
Tyrosine Kinase Inhibitor
6%
Non-adherence
6%
Re-exposure
6%
Minimal Residual Disease
6%
Methotrexate
6%
Pulmonary Embolism
6%
Single nucleotide Polymorphism
6%
Pancreas
5%
Polyethylene
5%
Maintenance Risk
5%
Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
5%
ADAMTS13
5%
Network Meta-analysis
5%
Imatinib
5%
Escherichia Coli
5%
Thioguanine
5%
Thiopurines
5%
Escherichia Hermannii
5%
Allogeneic Transplantation
5%
Improved Survival
5%
Population-based Study
5%
Danish Population
5%
Cerebral Venous Thrombosis
5%
Acute Lymphoblastic Leukemia Survivors
5%
Histomorphological
5%
Therapeutic Drug Monitoring
5%
Leukemia
5%
Polygenic Risk Score Analysis
5%
Inflammatory Bowel Disease
5%
Hemodialysis Patients
5%
Response Pattern
5%
Endothelial Dysfunction
5%
Essential Thrombocythemia
5%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
96%
Asparaginase
38%
Thromboembolism
25%
Mercaptopurine
15%
Tioguanine
11%
Pancreatitis
8%
Bone Necrosis
8%
Protein Tyrosine Kinase Inhibitor
7%
Hepatotoxicity
7%
Observational Study
6%
Methotrexate
6%
Thrombosis
6%
Lung Embolism
6%
Imatinib
5%
Prevalence
5%
Venous Thromboembolism
5%
Leukemia
5%
Endothelial Dysfunction
5%
Therapeutic Drug Monitoring
5%
Inflammatory Bowel Disease
5%
Escherichia coli
5%
Philadelphia 1 Chromosome
5%
Antithrombin
5%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
63%
Asparaginase
19%
Thromboembolism
17%
Pediatric Oncology
13%
Pediatric Hematology
13%
Pancreatitis
11%
Minimal Residual Disease
7%
Observational Study
6%
Venous Thromboembolism
6%
Overall Survival
6%
Systematic Review
6%
Pulmonary Embolism
6%
Maintenance Therapy
5%
Thrombotic Thrombocytopenic Purpura
5%
Von Willebrand Factor Cleaving Proteinase
5%
Bone Necrosis
5%
Allotransplantation
5%
Polycythemia vera
5%
Alpha2 Interferon
5%
Essential Thrombocythaemia
5%
Liver Toxicity
5%
Sequela
5%
Escherichia
5%
Tioguanine
5%
Hemodialysis
5%
Antibiotic Therapy
5%
Inflammatory Bowel Disease
5%
Sepsis
5%
Infection
5%
Antithrombin
5%
